Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 8/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766118 | 0.88 | RBP4 (0.43) | RBP4MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL766175 | 0.87 | RBP4 (0.47) | RBP4MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL766126 | 0.86 | RBP4 (0.41) | RBP4HSD11B1MAPTALDH1A1LMNA | |
| SCHEMBL766213 | 0.85 | RBP4 (0.40) | RBP4MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL766232 | 0.84 | RBP4 (0.40) | RBP4HSD11B1MAPTALDH1A1LMNA | |
| SCHEMBL766070 | 0.79 | RBP4 (0.73) | RBP4PTGDR2MAPTALDH1A1HPGD | |
| SCHEMBL631571 | 0.75 | RBP4 (0.48) | RBP4BRD4PTGDR2HSD11B1MAPT | |
| SCHEMBL766289 | 0.72 | RBP4 (0.74) | RBP4PTGDR2MAPTALDH1A1HPGD | |
| SCHEMBL632040 | 0.72 | RBP4 (1.00) | RBP4PTGDR2MAPTALDH1A1LMNA | |
| SCHEMBL30996959 | 0.72 | RBP4 (1.00) | RBP4PTGDR2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885BRD4 143/4885PTGDR2 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.